Vistagen Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before March 16, 2026 to Discuss Your Rights – VTGN

Core Viewpoint - Vistagen Therapeutics, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding its Phase 3 PALISADE-3 trial of fasedienol, which did not meet its primary endpoint, leading to a significant drop in stock price [3][4]. Group 1: Company Overview - Vistagen Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for social anxiety disorder [3]. - The company’s investigational drug, fasedienol, was under evaluation in the Phase 3 PALISADE-3 trial [3]. Group 2: Trial Results and Allegations - The PALISADE-3 trial did not show a statistically significant improvement on the primary endpoint, which was the change on the Subjective Units of Distress Scale [3]. - Defendants allegedly provided positive statements while concealing adverse facts about the trial results [3]. Group 3: Stock Price Impact - Following the announcement of the trial results on December 17, 2025, Vistagen's stock price plummeted from $4.36 per share to $0.86 per share, representing a decline of over 80% [3]. Group 4: Legal Proceedings - Shareholders who purchased shares during the class period from April 1, 2024, to December 16, 2025, are encouraged to register for the class action lawsuit [4]. - The deadline for shareholders to seek lead plaintiff status is March 16, 2026 [4].